Management of Uncomplicated Non‑Purulent Cellulitis in Healthy Adults

Antibiotic Selection

• β‑lactam antibiotics are the cornerstone of therapy because non‑purulent cellulitis is predominantly caused by β‑hemolytic streptococci and methicillin‑sensitive Staphylococcus aureus (MSSA). 1
• For an otherwise healthy adult, prescribe a β‑lactam targeting streptococci (e.g., cephalexin 500 mg four times daily or penicillin V 500 mg four times daily) for a 5‑day course. 1
• Routine addition of MRSA‑directed agents such as trimethoprim‑sulfamethoxazole or doxycycline is not recommended for typical non‑purulent cellulitis unless specific risk factors are present. 1

When to Add MRSA Coverage

• Expand therapy to include MRSA‑active agents only if any of the following are present:
• If MRSA coverage is indicated, use vancomycin 15–20 mg/kg IV every 8–12 hours or another agent with activity against both MRSA and streptococci. [2][1]

Treatment Duration

• A 5‑day oral β‑lactam course is sufficient for uncomplicated cellulitis when clinical improvement is evident. 1
• Extend therapy beyond 5 days only if reassessment at 48–72 hours shows no improvement. 1

Setting of Care (Outpatient vs. Inpatient)

• Manage as an outpatient when the patient:
• Hospitalize and initiate IV antibiotics if any of the following occur:

Adjunctive Measures

• Elevate the affected limb to reduce edema and facilitate drainage of inflammatory mediators. 1
• Carefully examine interdigital toe spaces in lower‑extremity cellulitis; treat concomitant tinea pedis (e.g., with topical antifungals) to eradicate colonizing pathogens and lower recurrence risk. 1
• Identify and address predisposing factors such as venous insufficiency, lymphedema, or underlying dermatoses to minimize future episodes. 1

Diagnostic Pitfalls

• Do not obtain routine blood or tissue cultures in uncomplicated cases; yields are low (~15 %) and results rarely alter management in immunocompetent patients without systemic toxicity. 1
• Do not extend antibiotic courses beyond 5 days in patients showing clinical improvement, as this adds cost, adverse‑event risk (including C. difficile infection), and promotes resistance without improving outcomes. 1

Follow‑up and Escalation

• If there is failure to improve after 48–72 hours, consider:

Management of Lower Extremity Cellulitis with Bullae in Afebrile Patients

Indications for Empiric Antibiotic Therapy

• Cellulitis is a clinical diagnosis that warrants treatment even when fever and leukocytosis are absent, because the presence of bullae indicates deeper tissue involvement and a more severe infection. 3

First‑Line Antibiotic Regimen

• Initiate a β‑lactam agent active against β‑hemolytic streptococci (and methicillin‑sensitive Staphylococcus aureus) for an initial 5‑day course; oral cephalexin 500 mg four times daily or oral penicillin V 500 mg four times daily are appropriate options. 3

When to Add MRSA‑Directed Therapy

• Do not add MRSA coverage routinely; add agents such as vancomycin (15–20 mg/kg IV every 8–12 h) only if any of the following risk factors are present: penetrating trauma, documented MRSA infection or nasal colonization, injection drug use, purulent drainage (reclassifying the infection as purulent cellulitis), or fulfillment of SIRS criteria. 3

Treatment Duration and Monitoring

• Reassess clinical response after 48–72 hours; continue the initial 5‑day regimen if improvement is evident, and extend therapy only when the infection has not improved by that time point. 3

Outpatient vs. Inpatient Management Criteria

• Outpatient management is appropriate when the patient is hemodynamically stable, lacks SIRS criteria, has no altered mental status, and can ensure reliable follow‑up. 3
• Hospital admission and IV antibiotics are indicated if SIRS criteria develop, rapid clinical progression occurs, there is concern for deeper infection (e.g., necrotizing fasciitis), or oral therapy fails after 48–72 hours. 3

Adjunctive Non‑Antibiotic Measures

• Elevate the affected limb to reduce edema and promote resolution. 3
• Inspect interdigital spaces for tinea pedis and treat any fungal involvement with topical antifungals to decrease colonizing pathogens and recurrence risk. 3
• Address underlying predisposing conditions such as venous insufficiency, lymphedema, chronic leg ulcers, or other dermatoses. 3

Diagnostic Pitfalls

• Do not delay treatment awaiting fever or abnormal laboratory values; absence of these does not exclude cellulitis. 3
• Routine blood or tissue cultures are not recommended in uncomplicated cellulitis because yields are low (~15 %) and rarely change management in immunocompetent patients. 3
• Consider cultures only in severely immunocompromised patients, those with neutropenia, undergoing chemotherapy, or with immersion injuries/animal bites. 3
• If no improvement occurs after 48–72 hours of appropriate antibiotics, reassess the diagnosis for non‑infectious mimics (e.g., venous stasis dermatitis, deep‑vein thrombosis) or deeper infection. 3

Risk Factors for Treatment Failure

• Presence of chronic leg ulcers, chronic edema/lymphedema, prior cellulitis at the same site, cellulitis occurring at a wound, or fever at presentation increase the odds of treatment failure and may warrant closer monitoring, a lower threshold for hospitalization, or more aggressive initial therapy. 3